

CITATION REPORT

List of articles citing

Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial

DOI: 10.1186/s13063-016-1262-z
Trials, 2016, 17, 127.

Source: <https://exaly.com/paper-pdf/65229674/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
120	Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification. 2017 , 28, 2067-2076		48
119	Quality assurance of the PREOPANC trial (2012-003181-40) for preoperative radiochemotherapy in pancreatic cancer : The dummy run. 2017 , 193, 630-638		6
118	Addition of MRI for CT-based pancreatic tumor delineation: a feasibility study. 2017 , 56, 923-930		18
117	Dosimetric effects of anatomical changes during fractionated photon radiation therapy in pancreatic cancer patients. 2017 , 18, 142-151		9
116	Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. <i>Cancer Medicine</i> , 2017 , 6, 1552-1562	4.8	14
115	Preoperative predictors for early recurrence of resectable pancreatic cancer. 2017 , 15, 16		48
114	Considerable interobserver variation in delineation of pancreatic cancer on 3DCT and 4DCT: a multi-institutional study. 2017 , 12, 58		13
113	Correlation Between Preoperative Serum Carcinoembryonic Antigen Levels and Expression on Pancreatic and Rectal Cancer Tissue. 2017 , 9, 1179299X17710016		8
112	Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits. 2017 , 18,		49
111	Role of surgery in pancreatic cancer. 2017 , 23, 3765-3770		19
110	Pathological Margin Clearance and Survival After Pancreaticoduodenectomy in a US and European Pancreatic Center. 2018 , 25, 1760-1767		23
109	Neoadjuvant Treatment of Pancreatic Cancer. 2018 , 842-846		
108	How to treat borderline resectable pancreatic cancer: current challenges and future directions. 2018 , 48, 205-213		2
107	Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. 2018 , 105, 946-958		220
106	Therapeutic developments in pancreatic cancer: current and future perspectives. 2018 , 15, 333-348		423
105	Tumor manipulation during pancreatic resection for pancreatic cancer induces dissemination of tumor cells into the peritoneal cavity: a systematic review. <i>Hpb</i> , 2018 , 20, 289-296	3.8	3
104	Management of Borderline Resectable Pancreatic Cancer. 2018 , 100, 1155-1174		20

103	Preoperative CT in patients with surgically resectable pancreatic adenocarcinoma: does the time interval between CT and surgery affect survival?. 2018 , 43, 620-628		6
102	The clinical benefit of hyperthermia in pancreatic cancer: a systematic review. 2018 , 34, 969-979		27
101	Adjuvant or Neoadjuvant Therapy in the Treatment in Pancreatic Malignancies: Where Are We?. 2018 , 98, 95-111		18
100	Impact of sarcopenia in borderline resectable and locally advanced pancreatic cancer patients receiving stereotactic body radiation therapy. <i>Journal of Gastrointestinal Oncology</i> , 2018 , 9, 24-34	2.8	13
99	Neoadjuvant Treatment for Nonmetastatic Pancreatic Cancer. 2018 ,		1
98	Comparison of different treatment planning approaches for intensity-modulated proton therapy with simultaneous integrated boost for pancreatic cancer. 2018 , 13, 228		13
97	Recent treatment patterns and survival outcomes in pancreatic cancer according to clinical stage based on single-center large-cohort data. 2018 , 22, 386-396		7
96	FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study. 2018 , 118, 1021-1026		14
95	Association of the location of pancreatic ductal adenocarcinoma (head, body, tail) with tumor stage, treatment, and survival: a population-based analysis. 2018 , 57, 1655-1662		38
94	Association Between Very Small Tumor Size and Decreased Overall Survival in Node-Positive Pancreatic Cancer. 2018 , 25, 4027-4034		10
93	Evaluation of Six Diffusion-weighted MRI Models for Assessing Effects of Neoadjuvant Chemoradiation in Pancreatic Cancer Patients. 2018 , 102, 1052-1062		12
92	Systemic neoadjuvant chemotherapy in modern pancreatic cancer treatment: a systematic review and meta-analysis. 2019 , 101, 453-462		17
91	Yield of staging laparoscopy before treatment of locally advanced pancreatic cancer to detect occult metastases. 2019 , 45, 1906-1911		9
90	Treatment of mid-bile duct carcinoma: Local resection or pancreatoduodenectomy?. 2019 , 45, 2180-2187		4
89	Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderline Resectable Pancreatic Adenocarcinoma (HOPS-BR 01). 2019 , 105, 606-617		9
88	Author response to: Resection margin status in pancreatic cancer surgery: is it really less important than the N status?. 2019 , 106, 1559-1560		2
87	Unravelling the Diagnostic Dilemma: A MicroRNA Panel of Circulating MiR-16 and MiR-877 as A Diagnostic Classifier for Distal Bile Duct Tumors. 2019 , 11,		11
86	Significance of radiographic splenic vessel involvement in the pancreatic ductal adenocarcinoma of the body and tail of the gland. 2019 , 120, 262-269		4

85	Pancreatic cancer. 2019 , 37, 319-326		4
84	Impact of resection margin status on recurrence and survival in pancreatic cancer surgery. 2019 , 106, 1055-1065		80
83	Long-term outcome following neoadjuvant therapy for resectable and borderline resectable pancreatic cancer compared to upfront surgery: a meta-analysis of comparative studies by intention-to-treat analysis. 2019 , 49, 295-299		25
82	Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer. 2019 , 45, 1674-1683		30
81	Impact of expanding indications on surgical and oncological outcome in 1434 consecutive pancreatoduodenectomies. <i>Hpb</i> , 2019 , 21, 865-875	3.8	13
80	Nodal downstaging as a treatment goal for node-positive pancreatic cancer. 2019 , 165, 1144-1150		7
79	Time to Adjuvant Systemic Therapy Following Pancreatic Cancer Resection and Effect on Outcome. 2019 , 48, 1086-1091		11
78	Efficacy and feasibility of stereotactic radiotherapy after folfinirox in patients with locally advanced pancreatic cancer (LAPC-1 trial). 2019 , 17, 100200		22
77	Adjuvant and neoadjuvant therapy for pancreatic cancer. <i>Journal of Pancreatology</i> , 2019 , 2, 100-106	1.9	16
76	The Value of International Collaboration in Pancreatic Cancer Research: EURECCA. 2019 , 26, 705-706		2
75	Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2019 , 269, 1154-1162	7.8	120
74	The Systemic-immune-inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels: A Retrospective Multicenter Cohort Study. <i>Annals of Surgery</i> , 2019 , 270, 139-146	7.8	123
73	Imaging and Management of Pancreatic Cancer. <i>Seminars in Ultrasound, CT and MRI</i> , 2020 , 41, 139-151	1.7	1
72	Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma. 2020 , 125, 83-93		41
71	Neoadjuvant Therapy is Associated with Improved Survival in Borderline-Resectable Pancreatic Cancer. 2020 , 27, 1191-1200		17
70	Novel Radiotherapy Technologies in the Treatment of Gastrointestinal Malignancies. 2020 , 34, 29-43		2
69	Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. <i>Annals of Surgery</i> , 2020 , 271, 996-1002	7.8	19
68	Immunological Gene Signature Associated With the Tumor Microenvironment of Pancreatic Cancer After Neoadjuvant Chemotherapy. 2020 , 49, 1240-1245		1

67	The utilization and impact of adjuvant therapy following neoadjuvant therapy and resection of pancreatic adenocarcinoma: does more really matter?. <i>Hpb</i> , 2020 , 22, 1530-1541	3.8	3
66	Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard?. 2020 , 12, 1758835920936093		15
65	Pancreatectomy in Stage I pancreas cancer: national underutilization of surgery persists. <i>Hpb</i> , 2020 , 22, 1703-1710	3.8	3
64	Soluble Compounds Released by Hypoxic Stroma Confer Invasive Properties to Pancreatic Ductal Adenocarcinoma. 2020 , 8,		3
63	Impact of neoadjuvant therapy on post-operative pancreatic fistula: a systematic review and meta-analysis. 2020 , 90, 2201-2210		9
62	The yield of chest computed tomography in patients with locally advanced pancreatic cancer. 2020 , 122, 450-456		3
61	Optimal timing and treatment strategy for pancreatic cancer. 2020 , 122, 457-468		9
60	ASO Author Reflections: Serum CA19-9 Utility in Pancreatic Adenocarcinoma in Patients Undergoing Neoadjuvant Therapy. 2020 , 27, 2015-2016		1
59	Establishing and Coordinating a Nationwide Multidisciplinary Study Group: Lessons Learned by the Dutch Pancreatic Cancer Group. <i>Annals of Surgery</i> , 2020 , 271, e102-e104	7.8	18
58	Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI. 2020 , 26, 5007-5018		11
57	Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1763-1773	2.2	290
56	Neoadjuvant treatment for resectable pancreatic adenocarcinoma: What is the best protocol?. 2020 , 4, 100-108		18
55	Adjuvant and neoadjuvant treatment for pancreatic adenocarcinoma. 2020 , 50, 483-489		19
54	Conditional Survival After Resection for Pancreatic Cancer: A Population-Based Study and Prediction Model. 2020 , 27, 2516-2524		16
53	Does neoadjuvant therapy for pancreatic head adenocarcinoma increase postoperative morbidity? A systematic review of the literature with meta-analysis. 2020 , 121, 881-892		5
52	Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatoduodenectomy. 2020 , 167, 803-811		12
51	Response to Preoperative Therapy in Localized Pancreatic Cancer. 2020 , 10, 516		7
50	The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer. 2020 , 27, 3939-3947		7

49	Multidisciplinary consensus statement on the clinical management of patients with pancreatic cancer. 2020 , 22, 1963-1975		11
48	Pathological validation and prognostic potential of quantitative MRI in the characterization of pancreas cancer: preliminary experience. 2020 , 14, 2176-2189		9
47	Impact of Neoadjuvant Systemic Therapy on Pancreatic Fistula Rates Following Pancreatectomy: a Population-Based Propensity-Matched Analysis. 2021 , 25, 747-756		6
46	Nationwide practice and outcomes of endoscopic biliary drainage in resectable pancreatic head and periampullary cancer. <i>Hpb</i> , 2021 , 23, 270-278	3.8	2
45	ASO Author Reflections: Association Between Neoadjuvant Chemoradiotherapy and Intractable Serous Ascites After Pancreaticoduodenectomy for Pancreatic Cancer. 2021 , 28, 3798-3799		
44	Association Between Neoadjuvant Chemoradiotherapy and Intractable Serous Ascites After Pancreaticoduodenectomy for Pancreatic Cancer. 2021 , 28, 3789-3797		1
43	Microscopic resection margin status in pancreatic ductal adenocarcinoma - A nationwide analysis. 2021 , 47, 708-716		1
42	Transatlantic registries of pancreatic surgery in the United States of America, Germany, the Netherlands, and Sweden: Comparing design, variables, patients, treatment strategies, and outcomes. 2021 , 169, 396-402		11
41	The Artery-First Approach in Pancreatic Cancer Surgery. 2021 , 863-876		
40	Neoadjuvant and Adjuvant Therapy in Operable Pancreatic Cancer: Both Honey and Milk (but No Bread?). 2021 , 9, 1-12		2
39	Intact SMAD-4 is a predictor of increased locoregional recurrence in upfront resected pancreas cancer receiving adjuvant therapy. <i>Journal of Gastrointestinal Oncology</i> , 2021 , 12, 2275-2286	2.8	0
38	Pancreatic ductal adenocarcinoma and distal cholangiocarcinoma: a proposal of preoperative diagnostic score for differential diagnosis. 2021 , 19, 10		1
37	Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer. 2021 , 61-74		
36	Landmark Series: Neoadjuvant Treatment in Borderline Resectable Pancreatic Cancer. 2021 , 28, 1514-1520		3
35	Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial. 2021 , 21, 300		22
34	Staging Classification and Stratification of Pancreatic Cancer for Clinical Practice. 2021 , 433-442		
33	CA19.9 Serum Level Predicts Lymph-Nodes Status in Resectable Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Analysis. 2021 , 11, 690580		4
32	Preoperative serum ADAM12 levels as a stromal marker for overall survival and benefit of adjuvant therapy in patients with resected pancreatic and periampullary cancer. <i>Hpb</i> , 2021 ,	3.8	1

31	Predicting overall survival and resection in patients with locally advanced pancreatic cancer treated with FOLFIRINOX: Development and internal validation of two nomograms. 2021 , 124, 589-597		2
30	Survival Benefit Associated With Resection of Locally Advanced Pancreatic Cancer After Upfront FOLFIRINOX Versus FOLFIRINOX Only: Multicenter Propensity Score-matched Analysis. <i>Annals of Surgery</i> , 2021 , 274, 729-735	7.8	2
29	Risk factors for early morbidity and mortality following pancreatoduodenectomy with concomitant vascular reconstruction. 2021 , 68, 102587		1
28	Preoperative predictors for early and very early disease recurrence in patients undergoing resection of pancreatic ductal adenocarcinoma. <i>Hpb</i> , 2021 ,	3.8	0
27	Can a simplified CT response criteria for vascular involvement in pancreatic adenocarcinoma after neoadjuvant therapy predict survival in patients who achieved subsequent R0 resection?. 2021 , 46, 5609-5617		
26	Neoadjuvant treatment: A window of opportunity for nutritional prehabilitation in patients with pancreatic ductal adenocarcinoma. 2021 , 13, 885-903		2
25	Neoadjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma is Associated with Lower Post-Pancreatectomy Readmission Rates: A Population-Based Cohort Study. 2021 , 28, 1896-1905		2
24	Neoadjuvant and Adjuvant Radiotherapy in Operable Pancreatic Cancer. 2021 , 713-728		
23	Pancreatic Cancer. 2018 , 427-469		3
22	Neoadjuvant chemotherapy for primary resectable pancreatic cancer: a systematic review and meta-analysis. <i>Hpb</i> , 2020 , 22, 821-832	3.8	22
21	Clinical Utility of Histological and Radiological Evaluations of Tumor Necrosis for Predicting Prognosis in Pancreatic Cancer. 2020 , 49, 634-641		3
20	Surgical Complications in a Multicenter Randomized Trial Comparing Preoperative Chemoradiotherapy and Immediate Surgery in Patients With Resectable and Borderline Resectable Pancreatic Cancer (PREOPANC Trial). <i>Annals of Surgery</i> , 2020 ,	7.8	6
19	External Validity of the Multicenter Randomized PREOPANC Trial on Neoadjuvant Chemoradiotherapy in Pancreatic Cancer: Outcome of Eligible But Non-Randomized Patients. <i>Annals of Surgery</i> , 2020 ,	7.8	2
18	Clinical Outcomes of Biliary Drainage during a Neoadjuvant Therapy for Pancreatic Cancer: Metal versus Plastic Stents. <i>Gut and Liver</i> , 2020 , 14, 269-273	4.8	9
17	Pancreatic Resection After Neoadjuvant Treatment. 2017 , 221-229		
16	Neoadjuvant Chemoradiation for Localized Pancreatic Cancer. 2019 , 85-96		
15	Surgery with adjuvant or neoadjuvant treatment vs surgery alone for resectable pancreatic cancer: A network meta-analysis. <i>World Journal of Meta-analysis</i> , 2019 , 7, 309-322	0.5	
14	DUPLICATE: Imaging and Management of Pancreatic Cancer. <i>Seminars in Ultrasound, CT and MRI</i> , 2019 ,	1.7	

13	The role of radiation for pancreatic adenocarcinoma. <i>Journal of Pancreatology</i> , 2020 , 3, 72-80	1.9	2
12	High neutrophil-to-lymphocyte ratio following stereotactic body radiation therapy is associated with poor clinical outcomes in patients with borderline resectable and locally advanced pancreatic cancer.. <i>Journal of Gastrointestinal Oncology</i> , 2022 , 13, 368-379	2.8	1
11	Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102233	2.2	12
10	Location, Location, Location: What Should be Targeted beyond Gross Disease for Localized Pancreatic Ductal Adenocarcinoma (PDAC)? Proposal of a Standardized Clinical Tumor Volume (CTV) for PDAC of the Head: the "Triangle Volume".. <i>Practical Radiation Oncology</i> , 2022 ,	2.8	0
9	High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multi-agent chemotherapy.. <i>Cancer Medicine</i> , 2022 ,	4.8	2
8	Surgical resection is associated with improved long-term survival of patients with resectable pancreatic head cancer compared to multiagent chemotherapy.. <i>Hpb</i> , 2021 ,	3.8	
7	Treatment Response and Conditional Survival in Advanced Pancreatic Cancer Patients Treated with FOLFIRINOX: A Multicenter Cohort Study. <i>Journal of Oncology</i> , 2022 , 2022, 1-9	4.5	0
6	Role of CA 19.9 in the Management of Resectable Pancreatic Cancer: State of the Art and Future Perspectives. 2022 , 10, 2091		0
5	The yield of staging laparoscopy for resectable and borderline resectable pancreatic cancer in the PREOPANC randomized controlled trial. 2022 ,		0
4	Vasculitis, CA19-9, and PNI differentially predict response and surgical outcome in pancreatic ductal adenocarcinoma. 2023 ,		0
3	Early Recurrence after Upfront Surgery for Pancreatic Ductal Adenocarcinoma. 2023 , 30, 3708-3720		0
2	Defining the Optimal Duration of Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma. 2022 , 51, 1083-1091		0
1	Population-based impact of COVID-19 on incidence, treatment, and survival of patients with pancreatic cancer. 2023 ,		0